STANDARD BIOTOOLS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that STANDARD BIOTOOLS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $27.75M | Mar 8, 2018 |
| FY2017 | Sep 30, 2017 | $24.75M | Mar 8, 2018 |
| FY2017 | Jun 30, 2017 | $23.91M | Mar 8, 2018 |
| FY2017 | Mar 31, 2017 | $25.53M | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $25.08M | Mar 8, 2018 |
| FY2017 | Sep 30, 2016 | $22.19M | Mar 8, 2018 |
| FY2017 | Jun 30, 2016 | $28.17M | Mar 8, 2018 |
| FY2017 | Mar 31, 2016 | $29.00M | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | $30.72M | Mar 3, 2017 |
| FY2016 | Sep 30, 2015 | $28.64M | Mar 3, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.33M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $91.01M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $106.34M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $97.95M | Mar 11, 2025 |
| FY2022 | Dec 31, 2021 | $130.58M | Mar 14, 2023 |
| FY2020 | Dec 31, 2020 | $44.61M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $39.86M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $26.06M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $27.62M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $32.44M | Feb 25, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.54M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $44.88M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $50.45M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $37.05M | Mar 11, 2025 |
| FY2020 | Dec 31, 2020 | $22.08M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $20.80M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $11.83M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $13.00M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $17.54M | Feb 25, 2021 |
| FY2020 | Sep 30, 2019 | $13.84M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($74.90M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($138.89M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($74.66M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($190.10M) | Mar 11, 2025 |
| FY2022 | Dec 31, 2021 | ($59.24M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($53.02M) | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | ($64.79M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | ($59.01M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($60.54M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($75.99M) | Mar 18, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($110.25M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($127.49M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($76.60M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($116.21M) | Mar 11, 2025 |
| FY2022 | Dec 31, 2021 | ($67.46M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($51.04M) | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | ($51.84M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | ($48.16M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($58.36M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($73.19M) | Mar 18, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.99M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $28.83M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $25.95M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $37.38M | Mar 11, 2025 |
| FY2022 | Dec 31, 2021 | $37.94M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $36.46M | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | $31.64M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $30.03M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $30.83M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $38.42M | Mar 18, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.86M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $103.06M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $87.54M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $102.29M | Mar 11, 2025 |
| FY2022 | Dec 31, 2021 | $98.89M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $97.90M | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | $84.48M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $79.78M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $79.52M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $93.21M | Mar 18, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($74.34M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($143.45M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($43.29M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($89.37M) | Mar 11, 2025 |
| FY2022 | Dec 31, 2021 | ($44.06M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($15.42M) | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | ($35.21M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | ($25.20M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($24.10M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($39.14M) | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.30M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $8.36M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $2.83M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $3.83M | Mar 11, 2025 |
| FY2022 | Dec 31, 2021 | $13.26M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $12.72M | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | $2.53M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $372.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $1.57M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $5.07M | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $567.75M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $612.35M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $323.07M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $390.31M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $275.21M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $324.76M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $264.81M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $303.65M | Feb 27, 2020 |
| FY2018 | Jan 1, 2018 | $287.71M | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | $287.35M | Mar 18, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $143.46M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $140.62M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $159.87M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $160.52M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $180.62M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $185.71M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $111.20M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $231.53M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $256.42M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $253.16M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $424.29M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $471.72M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($148.05M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2022 | ($81.47M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2021 | $94.60M | Mar 11, 2025 |
| FY2022 | Dec 31, 2020 | $139.05M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $153.61M | Mar 8, 2022 |
| FY2021 | Dec 31, 2018 | $72.12M | Mar 8, 2022 |
| FY2018 | Jan 1, 2018 | $31.29M | Mar 18, 2019 |
| FY2020 | Dec 31, 2017 | $30.94M | Feb 25, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $111.30M | Mar 11, 2025 |
| FY2024 | Dec 31, 2023 | $106.32M | Mar 11, 2025 |
| FY2024 | Dec 31, 2022 | $106.25M | Mar 11, 2025 |
| FY2024 | Dec 31, 2021 | $106.38M | Mar 11, 2025 |
| FY2021 | Dec 31, 2020 | $106.56M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $104.11M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $104.11M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $104.11M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $104.11M | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | $104.11M | Mar 3, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.26B) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($1.19B) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($1.00B) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($926.10M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($736.00M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($676.76M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($623.64M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($558.85M) | Feb 27, 2020 |
| FY2018 | Jan 1, 2018 | ($499.84M) | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | ($500.20M) | Mar 18, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $120.86M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $166.73M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $51.70M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $81.31M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $28.45M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $68.52M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $21.66M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $95.40M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $58.06M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $35.05M | Mar 18, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $299.0K | Mar 11, 2025 |
| FY2024 | Dec 31, 2023 | $63.51M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $64.89M | Mar 1, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Mar 11, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Mar 8, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Mar 11, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 8, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Mar 8, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 386.38M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 377.53M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 80.23M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 79.48M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 76.92M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 74.54M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 69.96M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 49.34M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 38.79M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 29.21M | Mar 8, 2018 |